Compare MobilEye Global Inc (MBLY) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MobilEye Global Inc vs Repligen Corporation Common Stock — how do they compare? MobilEye Global Inc trades at $7.06 (market cap $6.08B), while Repligen Corporation Common Stock trades at $178.85 (market cap $11.31B). The key difference: Repligen Corporation Common Stock is the larger of the two by market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, MobilEye Global Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold MobilEye Global Inc for 15 Days and Repligen Corporation Common Stock for 0 Days on average.
| MBLY | RGEN | |
|---|---|---|
Market Cap | $6.08B | $11.31B |
Volume | 9,825,806 | 1,216,919 |
Sector | Consumer Cyclical | Health |
52-Week High | $15.33 | $194.57 |
52-Week Low | $6.56 | $102.87 |
Typical Hold Time | 15 Days | 0 Days |
Enterprise Value | $4.64B | $11.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mobileye Global (MBLY) trades at $7.02, up 2.63% with bearish technical signals despite recent earnings beats. The company shows mixed fundamentals with strong revenue growth to $2.0B in 2026 but deep net losses widening to -$4.1B. Analyst sentiment remains cautiously optimistic with 57.7% buy ratings and a $10.77 price target, while institutional interest persists through recent investments and insider buying.
MBLY presents a high-risk opportunity with significant upside potential if autonomous driving adoption accelerates, but faces substantial execution risks amid persistent losses and competitive pressures. The stock's current valuation below book value offers margin of safety, though profitability challenges and negative cash flow trends in 2026 require careful monitoring.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MobilEye Global Inc
Mobileye Global Inc. is a global leader in the development and deployment of Advanced Driver Assistance Systems (ADAS) and autonomous driving technologies. The company specializes in computer vision, machine learning, and data analysis to create sensing, mapping, and driving policy solutions. Mobileye's technology, including its EyeQ system-on-chips and its crowd-sourced mapping platform (REM), is integrated into vehicles worldwide, aiming to improve road safety and enable the future of autonomous mobility.
Read more on MBLY →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
